About Diane Hollenbaugh
Diane Hollenbaugh is a chief scientific officer at Bonum Therapeutics.
Diane Hollenbaugh first appears on SEC filings in 2021.
Experience
This experience comes from Diane Hollenbaugh's profile and from SEC filings. For roles taken from filings, the years are when the filings name Diane Hollenbaugh in the role, so the role may have started earlier or lasted longer.
Bonum Therapeutics, Inc. Current
Chief Scientific Officer
CSO (2022 – Present)
2021 – Present · Seattle, WA
Develops targeted protein medicines for people with cancer.
GI
Good Therapeutics, Inc.
CSO
2019 – 2022
AB
AbbVie Biotherapeutics
Executive Director, Immuno-Oncology Discovery
2013 – 2019
IG
Igenica
Sr. Dir. Antibody Discovery
2012 – 2013
DC
DH Biopharma Consulting
Biotech Consulting
2011 – 2012
ML
Merck Research Laboratories
Sr. Dir Antibody Technology and Oncology
2009 – 2010
SB
Schering-Plough Biopharma
Sr.Dir. Antibody Technology and Oncology
2007 – 2009
FI
FivePrime
VP Preclinical
2005 – 2007
ME
Medarex
Preclinical Biology
2002 – 2005
BS
Bristol-Myers Squibb
Immunology/Inflammation
1991 – 2002
Key Colleagues at Startups
The people Diane Hollenbaugh works with at each company, as listed on that company's latest Form D.
Bonum Therapeutics, Inc. · Form D, Apr 17, 2026
Samuel Bjork
Executive Chair
Monique Schiersing
Senior Investment Director, Roche Venture
Neela Patel
Chief Business Officer
JM
John McKearn
Director
Samuel Blackman
Independent Director
John Mulligan
Chief Executive Officer and director
Karl Handelsman
Founder & Managing Partner, Codon Capital, director
NW
Nicholas Walrod
Director
MM
Mitchell Mutz
Independent Director
Gaurav Aggarwal
Managing Partner, Vivo Capital and director